drugset

drugset / Trial / NCT04464642

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

NCT04464642 ↗

Phase 4 Unknown 110 enrolled Dr. Mohammad Mamun Khan

RandomizedParallel-groupOpen-labelTreatment

Summary

It is a randomized controlled study

Timeline

Start: 2019-07-10
Primary completion: 2020-08
Completion: 2020-09

Publications

Khan MM, Ahmed S, Hasan Sajib MK, Morshed AA, Mahbub-Uz-Zaman K, Haq SA. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial. Int J Rheum Dis. 2023 Sep;26(9):1729-1736. doi: 10.1111/1756-185X.14801. Epub 2023 Jun 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methotrexate	Small molecule	25 mg	Subcutaneous
Subject	Tofacitinib	Small molecule	10 mg	—

Indications